Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response

Pharmacogenomics

Volumn 11, Issue 6, 2010, Pages 747-761

  Balboa, Emilia ^a   Duran, Goretti ^b   Lamas, Maria Jesus ^b   Gomez Caamaño, Antonio ^b   Celeiro Muoz, Catuxa ^b   Lopez, Rafael ^b   Carracedo, Angel ^a,c   Barros, Francisco ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chemoradiotherapy; Hypermutability; Pharmacogenetics; Rectal cancer; Somatic mutation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CAPECITABINE; CETUXIMAB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; OXALIPLATIN; THYMIDYLATE SYNTHASE; VASCULOTROPIN RECEPTOR; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DNA; TUMOR MARKER;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPENIA; PHARMACOGENETICS; PREDICTION; PROTEIN BLOOD LEVEL; RECTUM CANCER; SIDE EFFECT; SOMATIC MUTATION; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROCEDURES; RECTAL NEOPLASMS; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DNA; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77952944679     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.51     Document Type: Article

References (94)

1. Smith DE, Muff NS, Shetabi H: Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. Am. J. Surg. 151, 577-580 (1986).
2. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G: Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 30, 169-175 (1994).
3. Sauer R, Becker H, Hohenberger W et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
4. Wheeler JM, Dodds E, Warren BF et al.: Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis. Colon Rectum 47, 2025-2031 (2004).
5. Carlomagno C, Farella A, Bucci L et al.: Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a Phase II study. Ann. Oncol. 20, 906-912 (2009).
6. Ugidos L, Delgado S, Conill C et al.: Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients. Invest. New Drugs 27, 262-268 (2009).
7. Bertolini F, Chiara S, Bengala C et al.: Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a Phase II study in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 73, 466-472 (2009).
8. Willett CG, Duda DG, di Tomaso E et al.: Effcacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fuorouracil in rectal cancer: a multidisciplinary Phase II study. J. Clin. Oncol. 27, 3020-3026 (2009).
9. Zhang N, Yin Y, Xu SJ, Chen WS: 5-fuorouracil: mechanisms of resistance and reversal strategies. Molecules 13, 1551-1569 (2008).
10. Gaughan DJ, Barbaux S, Kluijtmans LA, Whitehead AS: The human and mouse methylenetetrahydrofolate reductase (MTHFR) genes: genomic organization, mRNA structure and linkage to the CLCN6 gene. Gene 257, 279-289 (2000).
11. Ho DH, Townsend L, Luna M, Bodey GP: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fuorouracil as substrate. Anticancer Res. 6, 781-784 (1986).
12. Johnson MR, Hageboutros A, Wang K, High L, Smith JB and Diasio RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-defcient patient after treatment with topical 5-fuorouracil. Clin. Cancer Res. 5, 2006-2011 (1999).
13. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70 (2001).
14. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fuoropyrimidine-based chemotherapy. Clin. Cancer Res. 9, 1611-1615 (2003).
15. Johnson MR, Diasio RB: Importance of dihydropyrimidine dehydrogenase (DPD) defciency in patients exhibiting toxicity following treatment with 5-fuorouracil. Adv. Enzyme Regul. 41, 151-157 (2001).
16. Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 928-942 (2004).
17. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
18. Caldecotto KW: XRCC1 and DNA strand break repair. DNA Repair 2, 955-969 (2003).
19. Valerie K, Povirk LF: Regulation and mechanisms of mammalian double strand break repair. Oncogene 22, 5792-5812 (2003).
20. Murray D, Rosenberg E: The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat. Res. 364, 217-226 (1996).
21. Niedernhofer LJ, Odijk H, Budzowska M et al.: The structure-specifc endonuclease ERCC1-XPF is required to resolve DNA interstrand cross-link-induced double strand breaks. Mol. Cell. Biol. 24, 5776-5787 (2004).
22. Ahmad A, Robinson AR, Duensing A et al.: ERCC1-XPF endonuclease facilitates DNA double strand break repair. Mol. Cell. Biol. 28, 5082-5092 (2008).
23. Parshad R, Tarone RE, Price FM, Sanford KK: Cytogenetic evidence for differences in DNA incision activity in xeroderma pigmentosum group A, C and D cells after X-irradiation during G2 phase. Mutat. Res. 294, 149-155 (1993).
24. Satoh MS, Jones CJ, Wood RD, Lindahl T: DNA excision-repair defect of xeroderma pigmentosum prevents removal of a class of oxygen free radical-induced base lesions. Proc. Natl Acad. Sci. USA 90, 6335-6339 (1993).
25. Rzeszowska-Wolny J, Polanska J, Pietrowska M et al.: Infuence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by g radiation and its repair in lymphocytes in vitro. Radiat. Res. 164, 132-140 (2005).
26. Angelini S, Kumar R, Carbone F et al.: Micronuclei in humans induced by exposure to low level of ionizing radiation: infuence of polymorphisms in DNA repair genes. Mutat. Res. 570, 105-117 (2005).
27. Strimpakos AS, Syrigos KN, Saif MW: Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 9, 147-160 (2009).
28. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J. Clin. 59, 42-55 (2009).
29. Lamas MJ, Balboa E, Duran G et al.: Analysis of pharmacogenetic biomarkers in rectal patients trated with chemoradiotherapy. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 27(15S), E15051 (2009).
30. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ: Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur. J. Surg. Oncol. 32, 55-64 (2006).
31. Debucquoy A, Goethals L, Geboes K, Roels S, McBride WH, Haustermans K: Molecular responses of rectal cancer to preoperative chemoradiation. Radiother. Oncol. 80, 172-177 (2006).
32. Kuremsky JG, Tepper JE, McLeod HL: Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 74, 673-688 (2009).
33. Kikuchi M, Mikami T, Sato T et al.: High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br. J. Cancer 101, 116-123 (2009).
34. Stoehlmacher J, Goekkurt E, Mogck U et al.: Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fuorouracil-based chemoradiation. Cancer Lett. 272, 221-225 (2008).
35. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP: Epidermal growth factor and IR up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat. Res. 159, 439-452 (2003).
36. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S: MAPK pathways in radiation responses. Oncogene 22, 5885-15596 (2003).
37. Lindblom, A: Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr. Opin. Oncol. 13, 63-69 (2001).
38. Fernebro E, Halvarsson B, Baldetorp B, Nilbert M: Predominance of CIN versus MSI in the development of rectal cancer at young age. BMC Cancer 2, 25 (2002).
39. Gervaz P, Bucher P, Morel P: Two colons-two cancers: paradigm shift and clinical implications. J. Surg. Oncol. 88, 261-266 (2004).
40. Li FY, Lai MD: Colorectal cancer, one entity or three. J. Zhejiang Univ. Sci. B 10, 219-229 (2009).
41. Slattery ML, Curtin K, Wolff RK et al.: A comparison of colon and rectal somatic DNA alterations. Dis. Colon Rectum 52, 1304-1311 (2009).
42. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM: Divergent oncogenic changes infuence survival differences between colon and rectal adenocarcinomas. Dis. Colon Rectum 52, 1039-1045 (2009).
43. Lengauer C, Kinzler K W, Vogelstein B: Genetic instabilities in human cancers. Nature 396, 643-649 (1998).
44. Mandard AM, Dalibard F, Mandard JC et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11), 2680-2686 (1994).
45. Zarate RN, Arias F, Bandres E, Cubedo E, Malumbres R, Garcia-Foncillas J: Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J. Gastroenterol. 12, 6032 (2006).
46. Amador ML, Oppenheimer D, Perea S et al.: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64, 9139-9143 (2004).
47. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP: An empirical evaluation of multifarious outcomes in pharmacogenetics: b-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet. Genomics 16, 705-711 (2006).
48. Showalter SL, Showalter TN, Witkiewicz A et al.: Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fuorouracil. Is it time to move forward? Cancer Biol. Ther. 7, 986-994 (2008).
49. De Mattia E, Toffoli G: C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fuoropyrimidine-based therapy personalisation. Eur. J. Cancer 45, 1333-1351 (2009).
50. Villafranca E, Okruzhnov Y, Dominguez MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19, 1779-1786 (2001).
51. Edler D, Glimelius B, Hallström M et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of beneft from adjuvant fuorouracil-based chemotherapy. J. Clin. Oncol. 20, 1721-1728 (2002).
52. Gusella M, Frigo AC, Bolzonella C et al.: Predictors of survival and toxicity in patients on adjuvant therapy with 5-fuorouracil for colorectal cancer. Br. J. Cancer 100, 1549-1557 (2009).
53. Morganti M, Ciantelli M, Giglioni B et al.: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur. J. Cancer 41, 2176 (2005).
54. Ikediobi ON: Somatic pharmacogenomics in cancer. Pharmacogenomics J. 8, 305-314 (2008).
55. McWhinney SR, McLeod HL: Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10, 489-493 (2009).
56. Marsh S: Concordance between tumor and germline DNA. In: Pharmacogenomics, Anticancer Drug Discovery, and Response. Innocenti F (Ed.). Humana Press, NY, USA, 91-101 (2009).
57. Kawakami K, Ishida Y, Danenberg KD, Omura K, Watanabe G, Danenberg PV: Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn. J. Cancer Res. 93, 1221-1229 (2002).
58. Uchida K, Hayashi K, Kawakami K et al.: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin. Cancer Res. 10, 433-439 (2004).
59. Jensen SA, Vainer B, Witton CJ, Jørgensen JT, Sørensen JB: Prognostic signifcance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncol. 47, 1054-1061 (2008).
60. Ooyama A, Okayama Y, Takechi T, Sugimoto Y, Oka T, Fukushima M: Genome-wide screening of loci associated with drug resistance to 5-fuorouracil-based drugs. Cancer Sci. 98, 577-583 (2007).
61. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM: Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classifcation to aid fuoropyrimidine therapy. Cancer Res. 66, 9369-9373 (2006).
62. Watson RG, Muhale F, Thorne L et al.: Association of copy number variants in colorectal liver metastases with 5-fuorouracil resistance. Annu. J. Clin. Oncol. 27, (2009) (Abstract E14502).
63. Lips EH, van Eijk R, de Graaf EJ et al.: Progression and tumor heterogeneity ana lysis in early rectal cancer. Clin. Cancer Res. 14, 772-781 (2008).
64. Losi L, Baisse B, Bouzourene H, Benhattar J: Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26, 916-922 (2005).
65. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J: Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int. J. Cancer 93, 346-352 (2001).
66. West CM, Elliott RM, Burnet NG: The genomics revolution and radiotherapy. Clin. Oncol. 19, 470-480 (2007).
67. Kim WC, Hong YC, Choi SK et al.: Relationship between XRCC1 polymorphism and acute complication of chemoradiation therapy in the patients with colorectal cancer. J. Korean Soc. Ther. Radiol. Oncol. 24, 30-36 (2006).
68. Zhang W, Park DJ, Lu B et al.: Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin. Cancer Res. 15, 600-605 (2005).
69. Grade M, Becker H, Ried T et al.: Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell. Oncol. 28, 71-84 (2006).
70. Sjöblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
71. Cheng XD, Lu WG, Ye F, Wan XY, Xie X: The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J. Exp. Clin. Cancer Res. 28, 91 (2009).
72. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fuorouracil-associated toxicity. Pharmacogenetics 12(7), 555-558 (2002).
73. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the effcacy and toxicity of 5-fuorouracil. Eur. J. Cancer 40(7), 939-950 (2004).
74. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional ana lysis and DNA polymorphism of the tandemly repeated sequences in the 5́-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
75. Kawakami K, Salonga D, Park JM et al.: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational effciency but not its gene expression. Clin. Cancer Res. 7(12), 4096-4101 (2001).
76. Johnston PG, Fisher ER, Rockette HE et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12(12), 2640-2647 (1994).
77. Mandola MV, Stoehlmacher J, Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5́ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63(11), 2898-2904 (2003).
78. Kawakami K, Watanabe G: Identifcation and functional ana lysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63(18), 6004-6007 (2003).
79. Mandola MV, Stoehlmacher J, Zhang W et al.: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14(5), 319-327 (2004).
80. Dotor E, Cuatrecases M, Martínez-Iniesta M et al.: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fuorouracil-based adjuvant treatment. J. Clin. Oncol. 24(10), 1603-1611 (2006).
81. Frosst P, Blom HJ, Milos R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10(1), 111-113 (1995).
82. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64(3), 169-172 (1998).
83. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fuorouracil and methotrexate. J. Natl Cancer Inst. 96(2), 134-144 (2004).
84. Etienne MC, Ilc K, Formento JL et al.: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fuorouracil sensitivity. Br. J. Cancer 90(2), 526-534 (2004).
85. Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD: Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 16(21), 6559-6573 (1997).
86. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD: Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22(6), 917-922 (2001).
87. Stoehlmacher J, Ghaderi V, Iobal S et al.: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21(4B), 3075-3079 (2001).
88. Lunn RM, Helzlsouer KJ, Parshad R et al.: XPD polymorphisms: effects on DNA repair profciency. Carcinogenesis 21(4), 551-555 (2000).
89. Stoehlmacher J, Park DJ, Zhang W et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91, 344-354 (2004).
90. Zárate RN, Arias F, Bandres E, Cubedo E, Malumbres R, García-Foncillas J: Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J. Gastroenterol. 12(37), 6032-6036 (2006).
91. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61(24), 8654-8658 (2001).
92. Gebhardt F, Zänker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274(19), 13176-13180 (1999).
93. Giralt JL, Aranzazu E, Manuel D et al.: Prognostic signifcance of epidermal growth factor receptor (EGFR) in patients with rectal cancer treated with preoperative radiotherapy: a GICOR study. Int. J. Radiat. Oncol. Biol. Physics 54, 98-99 (2002).
94. Graziano F, Ruzzo A, Loupakis F et al.: Pharmacogenetic profling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 26(9), 1427-1434 (2008).